NCCN Guidelines for Penile Carcinoma: Evaluation and Management
For newly diagnosed penile carcinoma, perform detailed physical examination with biopsy confirmation, followed by risk-stratified lymph node assessment using dynamic sentinel node biopsy (DSNB) for high-risk disease (≥T1b), and pursue organ-sparing surgery when oncologically safe.
Initial Diagnostic Evaluation
Primary Tumor Assessment
Conduct a thorough physical examination documenting 1:
- Lesion characteristics: morphology (papillary, nodular, ulcerative, or flat), exact size, precise location on penis
- Depth assessment: relationship to submucosa, tunica albuginea, urethra, corpus spongiosum, and corpus cavernosum
- Number and boundaries of all lesions
Obtain a pretreatment biopsy when malignancy is not clinically obvious or when nonsurgical treatment is planned (topical agents, laser, radiotherapy) 1. Use incisional or excisional biopsy rather than punch biopsy, as the latter may be insufficiently representative 2.
Advanced Imaging
- MRI of the penis when uncertainty exists regarding corporal invasion or feasibility of organ-sparing surgery (artificial erection not mandatory) 1
- Ultrasound as alternative if MRI unavailable 1
Lymph Node Evaluation
Clinical N0 (Non-Palpable Nodes)
Risk stratification determines management 1:
High-risk patients (T1b or higher): Offer surgical lymph node staging 1
- T1b = T1 with lymphovascular invasion OR poorly differentiated histology
- Any T2 or greater
T1a G2 disease: Discuss surveillance as alternative to surgical staging for patients willing to comply with strict follow-up 1
Low-risk (Tis, Ta, T1a G1): No further nodal assessment needed 2
Surgical Staging Technique for cN0
DSNB is the preferred method 1:
- Perform inguinal ultrasound FIRST with fine-needle aspiration cytology of sonographically abnormal nodes 1
- If DSNB unavailable and referral not feasible: offer inguinal lymph node dissection (open or video-endoscopic) 1
- DSNB demonstrates 97% sentinel node identification rate, 7% false-negative rate, and 4.7% complication rate 2
Clinical N+ (Palpable/Suspicious Nodes)
Obtain image-guided biopsy to confirm nodal metastasis before treatment 1. Note that approximately 50% of palpable nodes at diagnosis represent inflammatory changes, but nodes becoming palpable during follow-up are malignant in nearly 100% of cases 2.
Stage the pelvis and exclude distant metastases with 18F-FDG PET-CT or CT chest/abdomen before initiating treatment 1.
Primary Tumor Management
Superficial Noninvasive Disease (PeIN, Ta)
Surgical resection preferred over ablative/topical treatments because it provides complete histopathological staging and detects occult invasion (present in up to 20% of patients) 1.
Surgical options 1:
- Circumcision
- Wide local excision
- (Partial) glans resurfacing
- Recurrence rates: 0-20%
Topical alternatives (when surgery declined or not feasible) 1:
- Imiquimod: 40-100% response rate, 20% recurrence rate
- 5-Fluorouracil: 48-74% response rate, 11% recurrence rate
- Laser ablation (Nd:YAG or CO2): 52-100% response rate, 7-48% recurrence rate
Critical caveat: Clinically assess treatment effects and biopsy any areas of doubt, as insufficient responses may signify underlying invasive disease 1.
Invasive Disease (T1/T2)
Pursue organ-sparing surgery without compromising oncological control 1. The paradigm has shifted from requiring 2cm margins to accepting margins ≥5mm, which still achieve <5% recurrence rates 2.
Surgical margin requirement: ≥5mm is adequate for most tumors 2.
Important warning: Recent large series data challenges the old dogma that local recurrence has little influence on survival—patients with local recurrence after glansectomy for higher-risk tumors actually have poorer survival 1.
Lymph Node Management
Pathologic N1 (Single Positive Node)
Inguinal lymphadenectomy alone has curative potential 2.
Pathologic N2+ (≥2 Positive Nodes or Extranodal Extension)
Multimodal approach required 2:
- Consider adjuvant chemotherapy
- Perform pelvic lymph node dissection
- Consider postoperative radiotherapy
Fixed or Ulcerated Inguinal Nodes
Neoadjuvant chemoradiotherapy for fixed nodes 2:
- Responders receive consolidation surgery (bilateral deep ILND and ipsilateral pelvic LND if possible)
- Disease progression or unresectable nodes: additional systemic chemotherapy, local-field radiotherapy, or clinical trial
Critical Practice Gaps
Major deviation from guidelines exists in lymph node management 3. National data shows only 62.9% of patients with clinical N1/N2 disease undergo regional lymph node dissection, though this improved from 46.2% (2004) to 69.4% (2013). Patients at community cancer programs are significantly less likely to receive appropriate lymph node dissection compared to academic centers 3.
Systemic Therapy
For metastatic disease, cisplatin-based combination chemotherapy is standard 2, 4:
- Paclitaxel + Ifosfamide + Cisplatin (TIP regimen)
- Cisplatin + 5-FU or irinotecan combinations
Note: While NCCN-specific guidelines were requested, the most recent high-quality evidence comes from the 2023 EAU-ASCO collaborative guideline 1, which represents the current standard of care and is referenced throughout this response alongside ESMO 2 and NCCN 4 guidelines.